Chronic Myeloid Leukemia – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)
Key benefits and uses
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting
- Drill down into physicians’ treatment sequences and understand whom to position against or how to defend share
- Identify untapped treatment scenarios and key competitors to aid trial design
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages
- Discover untapped populations to expand product share and drive strategic decisions
Questions answered
- Where is my product positioned versus competitors in the treatment journey?
- What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
Geography
United States
Primary market research
Survey of 103 U.S. hematologist-oncologists
Product description
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.
Prateek Kumar, M.B.A., Associate Healthcare Research and Data Analyst, Oncology. Mr. Prateek conducts primary and secondary market research in the major pharmaceutical markets for various oncology indications. Prior to joining Clarivate, he was a lead associate at DelveInsight Business Research where he wrote epidemiology and market-based reports. He obtained his master’s degree in pharmaceutical management from Jamia Hamdard University in New Delhi.